Affinage

SIK2

Serine/threonine-protein kinase SIK2 · UniProt Q9H0K1

Length
926 aa
Mass
103.9 kDa
Annotated
2026-04-28
92 papers in source corpus 36 papers cited in narrative 36 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SIK2 is an AMPK-related serine/threonine kinase that functions as a central integrator of nutrient, hormonal, and stress signals, coupling upstream regulation by LKB1, PKA, CaMK I/IV, and CK1α to the phosphorylation of diverse substrates that control metabolism, gene expression, mitosis, autophagy, and DNA repair. Its best-characterized function is phosphorylation of CRTC/TORC coactivators and class IIa HDACs, promoting their 14-3-3-dependent cytoplasmic retention and thereby suppressing CREB- and MEF2-dependent transcription programs involved in melanogenesis, osteoblast RANKL expression, neuronal survival, adipocyte glucose homeostasis, and pulmonary fibrosis (PMID:20819186, PMID:23393134, PMID:24898145, PMID:30377251, PMID:40609791). SIK2 additionally phosphorylates p300-Ser89 to regulate PPARα-mediated ketogenesis, p35/CDK5R1-Ser91 to control β-cell insulin secretion via PJA2-dependent ubiquitylation, p97/VCP to stimulate ERAD, Drp1-Ser616 to promote mitochondrial fission, MYLK-Ser343 to activate cancer cell motility, LRP6 to engage Wnt/β-catenin signaling, Gab1-Ser266 to provide negative feedback on FGF2/ERK signaling, and GABARAPL2-Ser72 to enable autophagosome–lysosome fusion (PMID:26983400, PMID:24561619, PMID:24129571, PMID:31639424, PMID:35278271, PMID:35277657, PMID:39267218, PMID:41126299). SIK2 localizes to centrosomes where it phosphorylates C-Nap1 at Ser2392 to drive centrosome splitting and is required for mitotic fidelity, and its own activity is tuned by PKA-mediated Ser358 phosphorylation (promoting 14-3-3 binding and cytoplasmic relocalization), p300/CBP acetylation of Lys53 (inhibiting kinase activity), HDAC6 deacetylation (restoring activity), CaMK I/IV phosphorylation at Thr484 (triggering degradation), and Fbxw7-mediated proteasomal turnover (PMID:20708153, PMID:22462548, PMID:23322770, PMID:21220102, PMID:32437091).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2008 High

    Establishing SIK2 as a nutrient-responsive kinase that represses lipogenic gene expression independently of AMPK answered whether SIK2 has autonomous metabolic-sensing function in adipocytes.

    Evidence In vitro kinase assay, adenoviral overexpression/knockdown in adipocytes, SREBP-1 nuclear fractionation

    PMID:18239551

    Open questions at the time
    • Direct substrate on SREBP-1 nuclear translocation not identified
    • Upstream activating kinase not yet characterized in this system
  2. 2010 High

    Discovery that SIK2 localizes to centrosomes and phosphorylates C-Nap1 at Ser2392 to initiate centrosome splitting established SIK2 as a mitotic kinase, resolving how centrosome disjunction is linked to AMPK-family signaling.

    Evidence Immunofluorescence/fractionation, phosphosite mutagenesis, siRNA depletion with mitotic phenotype, xenograft models

    PMID:20708153

    Open questions at the time
    • Full spectrum of centrosomal substrates unknown
    • Whether SIK2 centrosomal function is LKB1-dependent not tested
  3. 2010 High

    Demonstration that SIK2 represses CREB-mediated MITF transcription by retaining TORC1 in the cytoplasm, with Sik2-knockout mice showing coat-color switching, established the TORC/CRTC-phosphorylation axis as a major SIK2 effector pathway in vivo.

    Evidence Sik2−/− mice on Ay/a background, dominant-negative TORC1 epistasis, melanogenesis assays

    PMID:20819186

    Open questions at the time
    • Specific TORC1 phosphorylation site by SIK2 not mapped in this study
    • Whether SIK1/SIK3 compensate partially not addressed
  4. 2011 High

    Identification of CaMK I/IV as upstream kinases that phosphorylate SIK2 at Thr484, triggering its degradation and thereby permitting TORC1 nuclear translocation and CREB-dependent neuronal survival, revealed how ischemic stress inactivates SIK2.

    Evidence In vitro kinase assay, sik2−/− neurons with OGD survival, transient focal ischemia model

    PMID:21220102

    Open questions at the time
    • Degradation pathway (proteasomal vs lysosomal) not defined
    • Whether Thr484 phosphorylation has distinct effects in non-neuronal cells not tested
  5. 2012 High

    Mapping PKA phosphorylation of SIK2 at Ser358 as the event that triggers 14-3-3 binding and cytoplasmic relocalization defined the molecular switch by which cAMP signaling inactivates SIK2 in adipocytes.

    Evidence Phosphopeptide mapping, S358A/S587A mutagenesis, 14-3-3 binding assay, subcellular fractionation

    PMID:22462548

    Open questions at the time
    • Whether 14-3-3 binding directly inhibits kinase activity or only controls localization not distinguished
    • Identity of the phosphatase reversing Ser358 phosphorylation unknown
  6. 2013 High

    Three concurrent studies established the breadth of SIK2 substrates: LKB1-activated SIK2 phosphorylates class IIa HDACs for 14-3-3-mediated nuclear export and MEF2 derepression; p300/CBP acetylation at Lys53 inhibits SIK2 while HDAC6 deacetylation restores it, linking SIK2 activity to autophagosome–lysosome fusion; and SIK2 phosphorylates p97/VCP to stimulate ERAD.

    Evidence In vitro kinase assays, co-immunoprecipitation, K53Q/K53R mutagenesis, autophagy flux assays, ERAD substrate degradation assays, epistasis experiments

    PMID:23322770 PMID:23393134 PMID:24129571

    Open questions at the time
    • Structural basis for Lys53 acetylation inhibiting kinase activity unknown
    • p97/VCP phosphorylation site not mapped
    • How SIK2 kinase activity mechanistically drives autophagosome–lysosome fusion not fully resolved
  7. 2014 High

    SIK2 was placed at the center of adipocyte glucose homeostasis and β-cell insulin secretion: SIK2 KO mice showed CRTC2-CREB dysregulation, GLUT4 loss, and impaired adiponectin secretion, while in β-cells SIK2 phosphorylates p35-Ser91 to trigger PJA2-mediated ubiquitylation and promote glucose-stimulated insulin secretion.

    Evidence Sik2 KO mice with metabolic phenotyping, β-cell-specific KO, co-IP of SIK2-p35-PJA2 complex, in vitro kinase assay, mass spectrometry

    PMID:24561619 PMID:24898145 PMID:25472719

    Open questions at the time
    • How SIK2 controls GLUT4 protein levels mechanistically (transcriptional vs post-translational) not resolved
    • Whether p35 phosphorylation by SIK2 occurs in non-β-cell tissues unknown
  8. 2016 High

    SIK2 was shown to phosphorylate p300 at Ser89 to disrupt its interaction with PPARα and suppress ketogenic gene expression, and catalytically inactive SIK2 knock-in mice revealed SIK2's role in macrophage anti-inflammatory polarization, broadening SIK2's functions to metabolic gene regulation and innate immunity.

    Evidence In vitro kinase assay (p300-Ser89), S89A mutagenesis, liver ketogenic gene expression; catalytically inactive KI mice, primary macrophage cytokine profiling

    PMID:26983400 PMID:27920213

    Open questions at the time
    • Direct SIK2 substrate(s) controlling macrophage polarization downstream of HDAC phosphorylation not identified
    • Whether p300-Ser89 phosphorylation affects other p300 interactions unknown
  9. 2016 High

    SIK2 inhibition was found to increase autophagic flux and cause selective death in triple-negative breast cancer cells, with ATG5 depletion rescuing cell death, establishing SIK2 as a restraint on autophagy in cancer.

    Evidence siRNA knockdown, pharmacological inhibition, ATG5 epistasis, xenograft models

    PMID:27697861

    Open questions at the time
    • Direct autophagy substrate of SIK2 not identified in this study
    • Whether SIK2-autophagy axis operates in non-cancer cells unknown
  10. 2018 High

    PTH-induced SIK2/SIK3 inhibition via PKA was shown to permit CRTC2/3 nuclear translocation and CREB-dependent RANKL transcription in osteoblasts, and insulin was found to induce SIK2-Thr484 phosphorylation for protein stabilization in adipocytes, extending the SIK2-CRTC axis to bone biology and linking insulin signaling to SIK2 turnover.

    Evidence siRNA epistasis in osteoblasts, CRTC nuclear localization imaging, qPCR for RANKL; phospho-Thr484 antibodies, proteasome inhibitor, primary human adipocytes

    PMID:30377251 PMID:30586628

    Open questions at the time
    • Kinase responsible for insulin-induced Thr484 phosphorylation not identified
    • Whether Thr484 phosphorylation is impaired in type 2 diabetes tissue in vivo not confirmed
  11. 2021 High

    SIK2 was identified as an actin-associated kinase recruited to the Salmonella-containing vacuole where it orchestrates Arp2/3- and Formin-dependent actin polymerization for xenophagy, and FANCA was found to co-localize with SIK2 at centrosomes and regulate its mitotic function, expanding SIK2's roles to host defense and the spindle assembly checkpoint.

    Evidence Global phosphoproteomics, SIK2 depletion with bacterial escape/xenophagy assays, co-localization at SCV; CRISPR synthetic lethality screen, FANCA-SIK2 co-localization, cell cycle assays

    PMID:33947818 PMID:34058059

    Open questions at the time
    • Direct SIK2 substrates at the SCV not identified
    • Mechanism by which FANCA modulates SIK2 kinase activity not reconstituted in vitro
    • Whether SIK2 phosphorylates actin regulators directly unknown
  12. 2022 High

    Four new direct substrates were identified: MYLK-Ser343 (activating myosin light chain and cancer motility), LRP6 (activating Wnt/β-catenin for breast cancer stemness), and class IIa HDACs driving MEF2D-dependent DNA repair gene expression (creating PARP inhibitor synthetic lethality), demonstrating the remarkable substrate diversity of SIK2.

    Evidence In vitro kinase assays for MYLK and LRP6, ChIP-seq/ATAC-seq for MEF2D, xenograft and zebrafish models, pharmacological and genetic inhibition

    PMID:35277657 PMID:35278271 PMID:35642638

    Open questions at the time
    • Structural basis for SIK2 substrate recognition across diverse targets unknown
    • Whether MYLK phosphorylation operates in non-cancer contexts not tested
    • LRP6 phosphorylation site not mapped
  13. 2024 High

    SIK2 was shown to phosphorylate Gab1 at Ser266 to weaken Gab1-Grb2/Shp2 interactions, providing negative feedback on FGF2/ERK signaling, and to promote RAD50-Ser635 phosphorylation required for nuclear RAD50 translocation and homologous recombination repair.

    Evidence In vitro kinase assay (Gab1-Ser266), co-IP of disrupted Gab1 complexes, ERK activation readouts; phospho-RAD50-S635 antibodies, HR repair assays, ovarian cancer organoids and xenografts

    PMID:38518726 PMID:39267218

    Open questions at the time
    • Direct in vitro kinase assay for RAD50 not described
    • Whether Gab1 phosphorylation extends to other RTK signaling contexts not tested
  14. 2025 High

    SIK2 was demonstrated to phosphorylate GABARAPL2 at Ser72, a modification essential for autophagosome–lysosome fusion; phosphomimetic GABARAPL2-S72E rescued autophagic flux and ameliorated amyloid pathology in 5×FAD Alzheimer's mice, providing the first direct SIK2 substrate in the autophagy machinery.

    Evidence GST pull-down, phosphoproteomics, S72E/S72A mutagenesis, AAV delivery in 5×FAD mice, mRFP-GFP-LC3 flux, electron microscopy, electrophysiology

    PMID:41126299

    Open questions at the time
    • Whether SIK2 phosphorylates other ATG8-family members unknown
    • Upstream signal controlling SIK2-GABARAPL2 axis in neurons not identified
  15. 2025 High

    Systematic siRNA epistasis in osteoblasts confirmed CRTC2 as the primary coactivator downstream of SIK2/3 for RANKL transcription and identified PP1/PP2A/PP4/PP5 as the phosphatases counteracting SIK2-mediated CRTC phosphorylation.

    Evidence Systematic siRNA of SIK1/2/3, CRTC1/2/3, PP1–PP7; quantitative immunofluorescence, co-IP, qPCR; primary mouse calvarial osteoblasts

    PMID:40609791

    Open questions at the time
    • Specific CRTC2 phosphorylation sites targeted by SIK2 in osteoblasts not mapped
    • Whether PP4/PP5 are direct SIK2-CRTC2 phosphatases or act indirectly not resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • Despite identification of over a dozen direct substrates, the structural basis for SIK2's broad substrate recognition, the relative contribution of individual substrates to in vivo phenotypes, and whether SIK2 functions as a monomer or within stable signaling complexes remain unresolved.
  • No crystal structure of SIK2 kinase domain with substrate peptide available
  • Tissue-specific substrate hierarchy not systematically defined
  • Potential scaffolding or complex-forming roles of SIK2 not characterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 14 GO:0098772 molecular function regulator activity 2 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0005815 microtubule organizing center 3 GO:0005783 endoplasmic reticulum 1 GO:0005829 cytosol 1 GO:0005856 cytoskeleton 1
Pathway
R-HSA-74160 Gene expression (Transcription) 7 R-HSA-1430728 Metabolism 5 R-HSA-1640170 Cell Cycle 3 R-HSA-9612973 Autophagy 3 R-HSA-162582 Signal Transduction 2 R-HSA-168256 Immune System 2 R-HSA-73894 DNA Repair 2 R-HSA-392499 Metabolism of proteins 1
Partners
CRTC2GABARAPL2HDAC4LRP6MYLKP35/CDK5R1P97/VCPPJA2

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 SIK2 localizes at the centrosome, plays a key role in the initiation of mitosis, and regulates the localization of the centrosome linker protein C-Nap1 through phosphorylation at S2392. PKA inhibition induces SIK2-dependent centrosome splitting in interphase, while SIK2 depletion blocks centrosome separation in mitosis. Subcellular localization (immunofluorescence/fractionation), phosphorylation site mutagenesis, siRNA depletion with mitotic phenotype readout, xenograft models Cancer cell High 20708153
2011 SIK2 suppresses CREB-mediated gene expression by phosphorylating and retaining TORC1 in the cytoplasm. During oxygen-glucose deprivation (OGD), CaMK I/IV phosphorylate SIK2 at Thr484, leading to SIK2 protein degradation and subsequent TORC1 dephosphorylation and nuclear translocation, activating CREB and promoting neuronal survival. In vitro kinase assay (CaMK I/IV phosphorylation of SIK2 at Thr484), sik2(-/-) mouse neurons with OGD survival readout, transient focal ischemia model Neuron High 21220102
2013 LKB1 activates SIK2 (and SIK3) to promote nuclear export of class IIa HDACs (HDAC4, -5, -7, -9) by phosphorylating them at conserved motifs that stimulate 14-3-3 binding. SIK2 activation of class IIa HDAC export is PKA-sensitive and activates MEF2-dependent transcription, relieving repression of myogenesis. In vitro kinase assay, co-immunoprecipitation, epistasis (LKB1→SIK2→HDAC→14-3-3), myogenesis reporter assays The Journal of biological chemistry High 23393134
2013 SIK2 kinase activity is regulated by reversible acetylation: p300/CBP-mediated acetylation of Lys-53 inhibits SIK2 kinase activity, while HDAC6-mediated deacetylation restores activity. Acetylation-mimetic SIK2 (K53Q) causes autophagosome accumulation, and SIK2 kinase activity is required for autophagosome-lysosome fusion and clearance of TDP-43Δ inclusion bodies. Site-directed mutagenesis (K53Q/K53R), in vitro kinase assay, co-immunoprecipitation with p300/HDAC6, autophagy flux assays, siRNA knockdown The Journal of biological chemistry High 23322770
2013 SIK2 physically interacts with p97/VCP (co-localizes in ER membrane), directly phosphorylates p97/VCP to stimulate its ATPase activity, and thereby promotes ER-associated protein degradation (ERAD). Kinase-deficient SIK2 or mutation of the SIK2 phosphorylation site on p97/VCP impairs ERAD substrate removal. Co-IP, co-localization (immunofluorescence), in vitro kinase assay, ERAD substrate degradation assays, siRNA knockdown The Journal of biological chemistry High 24129571
2014 SIK2 forms a complex with the CDK5 activator p35 (CDK5R1) and the E3 ligase PJA2. Upon glucose stimulation, SIK2 phosphorylates p35 at Ser91, triggering its ubiquitylation by PJA2 and promoting insulin secretion. β-cell-specific SIK2 knockout leads to p35 accumulation and impaired insulin secretion. Co-immunoprecipitation (SIK2-p35-PJA2 complex), in vitro kinase assay (SIK2 phosphorylates p35-Ser91), mass spectrometry (Gingras), β-cell-specific KO mice with glucose homeostasis phenotype Nature cell biology High 24561619
2014 In adipocytes, SIK2 directly phosphorylates CRTC2, CRTC3, and HDAC4. SIK2 interacts with CRTC2, CRTC3, HDAC4, and PP2A; cAMP elevation via PKA phosphorylation of SIK2 at Ser358 reduces its interaction with CRTCs and PP2A. SIK2 overexpression or activity increases GLUT4 protein levels and glucose uptake, while CRTC2/HDAC4 silencing recapitulates this effect. Co-immunoprecipitation, in vitro kinase assay, siRNA knockdown, glucose uptake assays, phosphosite mutagenesis (S358A) Journal of cell science High 25472719
2014 SIK2 KO mice exhibit dysregulated CRTC2-CREB transcriptional pathway in white adipocytes, increased ATF3 expression, downregulation of GLUT4, reduced high-molecular weight adiponectin, and impaired glucose uptake, establishing SIK2 as a critical regulator of adipocyte glucose and lipid homeostasis upstream of CRTC2-CREB. SIK2 knockout mice, CRTC2 KO mice (epistasis), 3T3-L1 adipocyte cultures, glucose/insulin tolerance tests Diabetes High 24898145
2012 PKA phosphorylates SIK2 at Ser358 in adipocytes in response to cAMP-elevating agents (forskolin, CL 316,243), leading to 14-3-3 binding. Ser358 phosphorylation (not Ser587) is required for 14-3-3 binding. This phosphorylation triggers relocalization of SIK2 from a particulate fraction to the cytosol in adipocytes. Phosphopeptide mapping, site-directed mutagenesis (S358A, S587A), 14-3-3 binding assay, immunocytochemistry, subcellular fractionation The Biochemical journal High 22462548
2010 SIK2 suppresses eumelanogenesis by phosphorylating and retaining TORC1 in the cytoplasm, thereby inhibiting CREB-mediated MITF gene expression. UV light exposure induces nuclear translocation of TORC1, which is blocked by SIK2. Sik2(-/-) mice on an A(y)/a background show brown (eumelanin) rather than yellow (pheomelanin) hair, demonstrating SIK2 represses eumelanogenesis in vivo. SIK2 knockout mice (genetic epistasis), dominant-negative TORC1 overexpression, B16 melanoma cell transfection, melanogenesis assays Pigment cell & melanoma research High 20819186
2016 SIK2 and SIK3 (particularly) control macrophage polarization; catalytically inactive knock-in of SIK2 and SIK3 shifts macrophages toward an anti-inflammatory phenotype (high IL-10, low TNFα). SIK2/SIK3 inhibition during macrophage differentiation produces a stable enhanced anti-inflammatory phenotype even after kinase reactivation. Catalytically inactive knock-in (KI) mice for SIK1/2/3, primary macrophage cytokine profiling, SIK inhibitor treatment (MRT199665, HG-9-91-01) The Biochemical journal High 27920213
2008 SIK2 is activated by nutrient deprivation, ATP synthesis inhibition, and AICAR in adipocytes. Activated SIK2 represses lipogenic gene expression (FAS, ACC2, SCD1) by reducing nuclear translocation of SREBP-1, independently of AMPK. This effect is reversed by constitutively active SREBP-1 overexpression. In vitro kinase assay (peptide substrate phosphorylation), adenovirus-mediated overexpression/knockdown, FAS promoter-luciferase reporter, SREBP-1 nuclear fractionation Obesity (Silver Spring, Md.) High 18239551
2016 SIK2 is required for restriction of autophagic flux in triple-negative breast cancer (TNBC) cells. Genetic or pharmacological SIK2 inhibition increases autophagic flux and causes selective cell death in breast cancer (especially claudin-low subtype) cells; ATG5 depletion rescues this cell death, placing SIK2 upstream of autophagosome formation. siRNA knockdown, pharmacological inhibition, ATG5 depletion rescue (epistasis), autophagic flux assays, xenograft models Molecular and cellular biology High 27697861
2016 SIK2 phosphorylates p300 at Ser89, disrupting the p300-PPARα interaction (p300 binds PPARα via a conserved LXXLL motif), thereby decreasing PPARα-mediated ketogenic gene expression during fasting. The phosphorylation-defective p300-S89A mutant shows increased interaction with PPARα and abolishes SIK2 suppression of ketogenesis. Co-immunoprecipitation (p300-PPARα), in vitro kinase assay (SIK2 phosphorylates p300-Ser89), site-directed mutagenesis (S89A), ketogenic gene expression in liver Scientific reports High 26983400
2018 In osteoblasts, PTH(1-34) inhibits SIK2 and SIK3 via PKA, leading to dephosphorylation and nuclear translocation of CRTC2/CRTC3 by protein phosphatases PP1/PP2A, resulting in CREB-mediated Rankl transcription. Knockdown of SIK2/3 and CRTC3 demonstrated their requirement in this signaling pathway. siRNA knockdown of SIK2/3 and CRTCs, immunofluorescence of CRTC nuclear localization, qPCR for Rankl expression, PP1/PP2A inhibition, primary osteoblasts The Journal of biological chemistry High 30377251
2019 SIK2 promotes mitochondrial fission through direct phosphorylation of Drp1 at Ser616, which inhibits mitochondrial oxidative phosphorylation and promotes the Warburg effect. SIK2 also upregulates HIF-1α by activating PI3K/AKT signaling to enhance glycolytic gene transcription in ovarian cancer cells. Phosphorylation assay (SIK2→Drp1-Ser616), PI3K/AKT pathway inhibition, HIF-1α reporter, mitochondrial morphology analysis, siRNA/overexpression in OC cells Cancer letters Medium 31639424
2020 SIK2 promotes lipid synthesis in ovarian cancer cells by upregulating SREBP1c (and downstream FASN) and SREBP2 (and downstream HMGCR) via the PI3K/Akt signaling pathway, enhancing both fatty acid and cholesterol synthesis. siRNA knockdown/overexpression, PI3K/Akt inhibition, SREBP1c/2 expression assays, in vitro and xenograft models Cell death & disease Medium 31932581
2013 SIK2 functions as a negative modulator of insulin-dependent Müller glia survival: insulin stimulation increases SIK2 activity and promotes IRS1-SIK2 interaction while modulating AKT phosphorylation. SIK2 knockdown under normo- and hyperglycemic conditions increases pAkt levels and reduces apoptosis, while SIK2 overexpression has the opposite effect. In vitro kinase assay (SIK2 activity), co-immunoprecipitation (IRS1-SIK2), siRNA knockdown and overexpression with pAkt/apoptosis readouts, streptozotocin rat model Investigative ophthalmology & visual science Medium 23599336
2020 SIK2 inhibits AKT/GSK3β/β-catenin signaling in gastric cancer by activating mTORC1 to inhibit autophagic degradation of protein phosphatases PHLPP2 and PP2A, which then dephosphorylate and inactivate AKT. siRNA knockdown/overexpression, Western blot for pAKT/GSK3β/β-catenin, mTORC1 inhibition (rapamycin), autophagy flux assays, in vitro migration/invasion assays Molecular oncology Medium 33128264
2015 B55gamma (PP2A regulatory subunit) binds SIK2 and stabilizes SIK2 protein, which is required for B55gamma-mediated suppression of S6K phosphorylation and enhanced glioma cell survival under glucose depletion. SIK2 knockdown in B55gamma-overexpressing cells recovers S6K phosphorylation. Co-immunoprecipitation, proteomic analysis, siRNA knockdown of SIK2, Western blot for pS6K, cell viability assays under glucose starvation Cancer cell international Medium 25792973
2022 SIK2 inhibition decreases phosphorylation of class-IIa HDACs (HDAC4/5/7), abolishes MEF2D transcriptional activity, and reduces MEF2D binding to regulatory regions of FANCD2, EXO1, and XRCC4 genes, thereby repressing DNA double-strand break repair and producing synthetic lethality with PARP inhibitors. SIK2 inhibitors (ARN3236, ARN3261), phospho-HDAC4/5/7 Western blot, ChIP-seq/ATAC-seq for MEF2D binding, DNA repair assays, xenograft models The Journal of clinical investigation Medium 35642638
2022 SIK2 directly phosphorylates MYLK (myosin light chain kinase) at Ser343, activating MYLK and its downstream substrate MYL2 (myosin light chain 2), thereby promoting ovarian cancer cell motility, migration, and metastasis. Adipocytes induce SIK2 phosphorylation at Ser358 and MYLK phosphorylation at Ser343, enhancing cancer cell motility. In vitro kinase assay (SIK2→MYLK-Ser343), phospho-specific antibodies, siRNA knockdown, migration/invasion/metastasis assays in vitro and in vivo Molecular oncology High 35278271
2022 SIK2 maintains breast cancer stem cell (BCSC) properties by directly phosphorylating LRP6 (LDL receptor-related protein 6) in a kinase-activity-dependent manner, leading to Wnt/β-catenin pathway activation and IDH1 induction, causing metabolic reprogramming. CK1α phosphorylates SIK2 upstream to enable this activity. In vitro kinase assay (SIK2→LRP6), siRNA knockdown, SIK2 inhibitor treatment (ARN-3236, HG-9-91-01), β-catenin accumulation assay, BCSC proportion/tumor initiation assays, zebrafish embryo model Oncogene High 35277657
2021 SIK2 associates with actin filaments under basal conditions and is recruited to the Salmonella-containing vacuole (SCV) together with Arp2/3 complex and Formins upon bacterial infection. SIK2 depletion causes actin nucleation/polymerization defects at the SCV, impairs xenophagy, and favors bacterial escape from the SCV, establishing SIK2 as an orchestrator of actin-dependent host defense. Global phosphoproteomics (identifying SIK2 upon Salmonella infection), siRNA depletion, co-localization (immunofluorescence of SIK2/Arp2/3/Formins at SCV), bacterial replication/xenophagy assays Proceedings of the National Academy of Sciences of the United States of America High 33947818
2020 Fbxw7 targets SIK2 for proteasomal degradation by binding to a conserved 'TPPPS' motif on SIK2. Loss of Fbxw7-mediated SIK2 degradation allows SIK2 to promote cell cycle progression and activation of the TORC2/AKT signaling pathway, modulating p21 expression in pancreatic cancer cells. Co-immunoprecipitation (Fbxw7-SIK2), protein database screening for Fbxw7-recognizing degron, proteasome inhibitor rescue, siRNA/overexpression with cell cycle/AKT readouts Cell biology international Medium 32437091
2014 SIK2 is critical for the development of cardiac left ventricular hypertrophy (LVH) in response to chronic high-salt diet. sik2(-/-) mice do not develop LVH upon high-salt feeding (unlike wild-type), and α-adducin regulates SIK2 expression in cardiomyocytes, which mediates adducin's effects on hypertrophy marker gene activation. sik2(-/-) mice with high-salt diet challenge, LV wall thickness echocardiography, gene expression profiling, siRNA of SIK2 in cardiomyocytes PloS one Medium 24752134
2020 Loss of PKA phosphorylation site Ser587 in SIK2 (Sik2S587A mice) increases NREM sleep delta density, establishing that PKA-SIK2 signaling regulates sleep need. Sik2S587A knock-in mice, EEG/EMG sleep recording, homeostatic sleep deprivation testing Scientific reports Medium 32457359
2023 LKB1 loss in uveal melanoma enhances proliferation and survival through SIK2 inhibition and upregulation of the Na+/Ca2+ exchanger SLC8A1, which promotes elevated intracellular calcium and mitochondrial ROS. CRISPR-Cas9 KO screen identified LKB1-SIK2 module as a tumor suppressor axis. Kinome-wide CRISPR-Cas9 KO screen, genetic epistasis (LKB1→SIK2→SLC8A1), calcium and ROS measurements, cell death assays with SLC8A1 inhibitor and mitochondria-targeted antioxidant EMBO molecular medicine Medium 37966164
2022 TGF-β1 induces SIK2 expression in lung fibroblasts, and SIK2 phosphorylates CRTC2 to retain it in the cytoplasm. SIK2 inhibition by ARN-3236 leads to CRTC2 dephosphorylation, nuclear translocation, and CREB-dependent anti-fibrotic gene expression, attenuating bleomycin-induced pulmonary fibrosis. Western blot (SIK2, p-CRTC2), ARN-3236 treatment, siRNA knockdown of SIK2, immunofluorescence (CRTC2 nuclear translocation), mouse bleomycin model BMC pulmonary medicine Medium 35410283
2024 SIK2 acts as a negative feedback regulator of FGF2/Ras/ERK1/2 signaling by phosphorylating Gab1 at Ser266, which weakens Gab1 interactions with Grb2 and Shp2. ERK1/2 activates SIK2 in this feedback loop. SIK2 downregulation enhances and prolongs ERK1/2 activation and increases FGF2-dependent cell proliferation. In vitro kinase assay (SIK2→Gab1-Ser266), site-directed mutagenesis, co-immunoprecipitation (Gab1-Grb2/Shp2), SIK2 overexpression/knockdown with pERK1/2 and proliferation readouts Advanced biology High 39267218
2025 SIK2 phosphorylates GABARAPL2 at Ser72, a modification essential for autophagosome-lysosome fusion. Phosphorylation-mimetic GABARAPL2-S72E rescues autophagic flux, reduces Aβ deposition, and restores synaptic function in 5×FAD Alzheimer's disease mice, while the non-phosphorylatable S72A mutant fails to show protective effects. Co-immunoprecipitation, GST pull-down assay, phosphoproteomics, site-directed mutagenesis (S72E/S72A), adeno-associated virus delivery in vivo, autophagy flux assays (mRFP-GFP-LC3), electron microscopy, Morris water maze, LTP recording Translational neurodegeneration High 41126299
2025 In osteoblasts, SIK2 (and SIK3) inhibition by PTH/PKA signaling allows CRTC2 nuclear translocation primarily via PP1/PP2A/PP4/PP5 action; CRTC2 is the primary co-activator of Tnfsf11 (RANKL) gene transcription, while SIK2/3 phosphorylation retains CRTCs in the cytoplasm. siRNA knockdown of SIK1/2/3, CRTC1/2/3, PP1/2/3/4/5/6/7; quantitative immunofluorescence of CRTC nuclear localization; co-immunoprecipitation; Western blot; qPCR for Tnfsf11; primary mouse calvarial osteoblasts The Journal of biological chemistry High 40609791
2024 SIK2 promotes RAD50 phosphorylation at Ser635, enabling nuclear translocation of RAD50 and nuclear filament assembly required for homologous recombination DNA repair. SIK2 inhibitor SIC-19 reduces RAD50-pS635, impairs nuclear RAD50 translocation, disrupts HR repair, and induces apoptosis in ovarian cancer cells. Phospho-specific antibodies (RAD50-pS635), SIK2 knockdown/SIC-19 inhibitor, nuclear translocation assays, HR repair assays, ovarian cancer organoids and xenograft models Drug resistance updates Medium 38518726
2018 Insulin induces phosphorylation of SIK2 at Thr484 in primary adipocytes, leading to increased SIK2 protein stability (prevented by proteasome inhibition). This Thr484 phosphorylation is impaired in insulin-resistant individuals but does not affect SIK2 catalytic activity toward HDAC4. Phospho-specific antibodies, in vitro kinase assay (SIK2 activity toward HDAC4), proteasome inhibitor (MG132), primary human and rat adipocytes Cellular signalling Medium 30586628
2021 SIK2 inhibition with MRIA9 blocks centrosome disjunction, impairs centrosome alignment, causes spindle mispositioning during mitosis, and increases chromosomal instability in ovarian cancer cells, corroborating SIK2's role as a centrosome kinase required for mitotic fidelity. Selective SIK2 inhibitor (MRIA9), live-cell imaging of centrosome dynamics, chromosomal instability assays, 3D-spheroid paclitaxel sensitivity assays Cancers Medium 34359562
2021 FANCA co-localizes with SIK2 at multiple mitotic structures and regulates SIK2 activity at centrosomes. Loss of FANCA exacerbates cell cycle defects from pharmacological SIK2 inhibition (impaired G2-M transition, delayed mitotic progression, cytokinesis failure). SIK2 inhibition also abrogates nocodazole-induced prometaphase arrest, revealing a role in the spindle assembly checkpoint. Kinome-wide synthetic lethality CRISPR screen, co-localization immunofluorescence (FANCA and SIK2 at centrosomes), pharmacological SIK2 inhibition in FANCA-/- cells, cell cycle assays, spindle assembly checkpoint assay Molecular oncology Medium 34058059

Source papers

Stage 0 corpus · 92 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer. Cancer letters 143 31639424
2011 SIK2 is a key regulator for neuronal survival after ischemia via TORC1-CREB. Neuron 130 21220102
2010 SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer cell 120 20708153
2013 The tumor suppressor kinase LKB1 activates the downstream kinases SIK2 and SIK3 to stimulate nuclear export of class IIa histone deacetylases. The Journal of biological chemistry 83 23393134
2015 SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes. Journal of cell science 79 25472719
2020 SIK2 enhances synthesis of fatty acid and cholesterol in ovarian cancer cells and tumor growth through PI3K/Akt signaling pathway. Cell death & disease 75 31932581
2022 FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability. International journal of biological sciences 72 36263177
2014 Role of the SIK2-p35-PJA2 complex in pancreatic β-cell functional compensation. Nature cell biology 69 24561619
2010 Downregulation of SIK2 expression promotes the melanogenic program in mice. Pigment cell & melanoma research 64 20819186
2016 Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages. The Biochemical journal 63 27920213
2014 SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in vivo. Diabetes 61 24898145
2012 The AMPK-related kinase SIK2 is regulated by cAMP via phosphorylation at Ser358 in adipocytes. The Biochemical journal 59 22462548
2018 Parathyroid hormone(1-34) and its analogs differentially modulate osteoblastic Rankl expression via PKA/SIK2/SIK3 and PP1/PP2A-CRTC3 signaling. The Journal of biological chemistry 57 30377251
2018 Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2. Journal of biochemical and molecular toxicology 44 30004169
2008 SIK2 can be activated by deprivation of nutrition and it inhibits expression of lipogenic genes in adipocytes. Obesity (Silver Spring, Md.) 43 18239551
2013 Reversible acetylation regulates salt-inducible kinase (SIK2) and its function in autophagy. The Journal of biological chemistry 42 23322770
2022 SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. The Journal of clinical investigation 33 35642638
2016 Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2). Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 33 27236538
2011 A potent inhibitor of SIK2, 3, 3', 7-trihydroxy-4'-methoxyflavon (4'-O-methylfisetin), promotes melanogenesis in B16F10 melanoma cells. PloS one 33 22022544
2022 SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Molecular oncology 32 35278271
2020 SIK2 represses AKT/GSK3β/β-catenin signaling and suppresses gastric cancer by inhibiting autophagic degradation of protein phosphatases. Molecular oncology 31 33128264
2021 The Selective SIK2 Inhibitor ARN-3236 Produces Strong Antidepressant-Like Efficacy in Mice via the Hippocampal CRTC1-CREB-BDNF Pathway. Frontiers in pharmacology 30 33519490
2021 Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis. Anti-cancer drugs 30 33735118
2020 Loss of the conserved PKA sites of SIK1 and SIK2 increases sleep need. Scientific reports 30 32457359
2020 Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis. European review for medical and pharmacological sciences 29 32016960
2020 CircAMOTL1 Promotes Tumorigenesis Through miR-526b/SIK2 Axis in Cervical Cancer. Frontiers in cell and developmental biology 29 33344445
2021 Fluoride Stimulates Anxiety- and Depression-like Behaviors Associated with SIK2-CRTC1 Signaling Dysfunction. Journal of agricultural and food chemistry 27 34735150
2016 SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival. Molecular and cellular biology 27 27697861
2018 SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways. Oncotarget 25 29774109
2022 SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/β-catenin signaling. Oncogene 24 35277657
2010 Amplification at 11q23 targets protein kinase SIK2 in diffuse large B-cell lymphoma. Leukemia & lymphoma 19 20367563
2024 Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases. Journal of medicinal chemistry 18 38552030
2021 MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54. Journal of translational medicine 17 34353336
2019 Parathyroid hormone (PTH) promotes ADSC osteogenesis by regulating SIK2 and Wnt4. Biochemical and biophysical research communications 17 31235257
2019 High-Throughput Implementation of the NanoBRET Target Engagement Intracellular Kinase Assay to Reveal Differential Compound Engagement by SIK2/3 Isoforms. SLAS discovery : advancing life sciences R & D 17 31849250
2014 Lack of salt-inducible kinase 2 (SIK2) prevents the development of cardiac hypertrophy in response to chronic high-salt intake. PloS one 17 24752134
2013 SIK2 is involved in the negative modulation of insulin-dependent muller cell survival and implicated in hyperglycemia-induced cell death. Investigative ophthalmology & visual science 17 23599336
2013 Interaction between salt-inducible kinase 2 (SIK2) and p97/valosin-containing protein (VCP) regulates endoplasmic reticulum (ER)-associated protein degradation in mammalian cells. The Journal of biological chemistry 17 24129571
2023 Discovery of novel and selective SIK2 inhibitors by the application of AlphaFold structures and generative models. Bioorganic & medicinal chemistry 16 37467565
2020 SIK2 Promotes Cisplatin Resistance Induced by Aerobic Glycolysis in Breast Cancer Cells through PI3K/AKT/mTOR Signaling Pathway. Bioscience reports 16 32458975
2021 The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells. Cancers 15 34359562
2023 LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition. EMBO molecular medicine 14 37966164
2021 Dasatinib-SIK2 Binding Elucidated by Homology Modeling, Molecular Docking, and Dynamics Simulations. ACS omega 14 34056256
2021 LINC00662 facilitates osteosarcoma progression via sponging miR-103a-3p and regulating SIK2 expression. Journal of tissue engineering and regenerative medicine 14 34559955
2015 The association between Salt-inducible kinase 2 (SIK2) and gamma isoform of the regulatory subunit B55 of PP2A (B55gamma) contributes to the survival of glioma cells under glucose depletion through inhibiting the phosphorylation of S6K. Cancer cell international 14 25792973
2021 The anti-rotavirus effect of baicalin via the gluconeogenesis-related p-JNK-PDK1-AKT-SIK2 signaling pathway. European journal of pharmacology 13 33567320
2016 SIK2 regulates fasting-induced PPARα activity and ketogenesis through p300. Scientific reports 13 26983400
2023 IGF2BP1 enhances the stability of SIK2 mRNA through m6A modification to promote non-small cell lung cancer progression. Biochemical and biophysical research communications 12 37866243
2022 Drug Repurposing: Escitalopram attenuates acute lung injury by inhibiting the SIK2/ HDAC4/ NF-κB signaling cascade. Biochemical and biophysical research communications 12 35158201
2022 Salt-inducible kinase 2 (SIK2) inhibitor ARN-3236 attenuates bleomycin-induced pulmonary fibrosis in mice. BMC pulmonary medicine 12 35410283
2022 SIK2 protects against renal tubular injury and the progression of diabetic kidney disease. Translational research : the journal of laboratory and clinical medicine 12 36075517
2025 SIK2 mediated mitochondrial homeostasis in spinal cord injury: modulating oxidative stress and the AIM2 inflammasome via CRTC1/CREB signaling. Journal of neuroinflammation 11 41339921
2022 SIK2 Improving Mitochondrial Autophagy Restriction Induced by Cerebral Ischemia-Reperfusion in Rats. Frontiers in pharmacology 11 35586047
2021 Antagonistic modulation of SIK1 and SIK2 isoforms in high blood pressure and cardiac hypertrophy triggered by high-salt intake. Clinical and experimental hypertension (New York, N.Y. : 1993) 11 33688765
2024 A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 10 38518726
2021 SIK2 orchestrates actin-dependent host response upon Salmonella infection. Proceedings of the National Academy of Sciences of the United States of America 10 33947818
2020 Tumor-suppressor Fbxw7 targets SIK2 for degradation to interfere with TORC2-AKT signaling in pancreatic cancer. Cell biology international 9 32437091
2000 The new serine-threonine kinase, Qik, is a target of the Qin oncogene. Biochemical and biophysical research communications 9 11027514
2025 Discovery of Novel SIK2/3 Inhibitors for the Potential Treatment of MEF2C+ Acute Myeloid Leukemia (AML). Journal of medicinal chemistry 8 40111261
2023 SIK2: A critical glucolipid metabolic reprogramming regulator and potential target in ovarian cancer. The journal of obstetrics and gynaecology research 8 37317594
2021 Exploring the stability of inhibitor binding to SIK2 using molecular dynamics simulation and binding free energy calculation. Physical chemistry chemical physics : PCCP 8 34086021
2023 Deficiency of salt-inducible kinase 2 (SIK2) promotes immune injury by inhibiting the maturation of lymphocytes. MedComm 7 37706195
2022 Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib. Computational and structural biotechnology journal 7 35685353
2022 Overexpression of circ PTK2 suppresses the progression of nonalcoholic fatty liver disease via the miR-200c/SIK2/PI3K/Akt axis. The Kaohsiung journal of medical sciences 6 35791807
2014 SIK2 regulates insulin secretion. Nature cell biology 6 24576898
2024 Discovery of the Natural Bibenzyl Compound Erianin in Dendrobium Inhibiting the Growth and EMT of Gastric Cancer through Downregulating the LKB1-SIK2/3-PARD3 Pathway. International journal of molecular sciences 5 39063214
2018 Insulin induces Thr484 phosphorylation and stabilization of SIK2 in adipocytes. Cellular signalling 5 30586628
2023 Inhibiting eukaryotic initiation factor 5A (eIF5A) hypusination attenuated activation of the SIK2 (salt-inducible kinase 2)-p4E-BP1 pathway involved in ovarian cancer cell proliferation and migration. Molecular biology reports 4 37219665
2021 SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells. Molecular oncology 4 34058059
2025 Activation of SIK2 inhibits gluconeogenesis and alleviates lipogenesis-induced inflammatory response by SIK2-CRTC2-ACC1 in hepatocytes of large yellow croaker (Larimichthys crocea). FASEB journal : official publication of the Federation of American Societies for Experimental Biology 3 40067199
2025 PTH stimulation of Rankl transcription is regulated by SIK2 and 3 and mediated by CRTC2 and 3 through action of protein phosphatases 1, 2, 4, and 5. The Journal of biological chemistry 3 40609791
2022 Designing of potent anti-diabetic molecules by targeting SIK2 using computational approaches. Molecular diversity 3 35727438
2025 Structure-Activity Relationship Guided Scaffold Hopping Resulted in the Identification of GLPG4970, a Highly Potent Dual SIK2/SIK3 Inhibitor. Journal of medicinal chemistry 2 40711360
2025 SIK2-mediated phosphorylation of GABARAPL2 facilitates autophagosome-lysosome fusion and rescues neurodegeneration in an Alzheimer's disease model. Translational neurodegeneration 2 41126299
2023 The AMPK-like protein kinases Sik2 and Sik3 interact with Hipk and induce synergistic tumorigenesis in a Drosophila cancer model. Frontiers in cell and developmental biology 2 37854071
2022 [Down-regulation of SIK2 expression alleviates myocardial ischemia-reperfusion injury in rats by inhibiting autophagy through the mTOR-ULK1 signaling pathway]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2 35869774
2021 Relationship between salt-inducible kinase 2 (SIK2) and lymph node metastasis in colorectal cancer patients complicated with chronic schistosomiasis. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2 34986532
2016 SIK2 Promotes Ovarian Cancer Spread. Cancer discovery 2 27604487
2025 Computational insights into marine natural products as potential antidiabetic agents targeting the SIK2 protein kinase domain. SAR and QSAR in environmental research 1 39773122
2025 SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers. Oncology research 1 40612876
2025 SIK2 Drives Pulmonary Fibrosis by Enhancing Fibroblast Glycolysis and Activation. Biomedicines 1 40868174
2024 SIK2 and SIK3 Differentially Regulate Mouse Granulosa Cell Response to Exogenous Gonadotropins In Vivo. Endocrinology 1 39158086
2024 SIK2 Controls the Homeostatic Character of the POMC Secretome Acutely in Response to Pharmacological ER Stress Induction. Cells 1 39329749
2026 Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes. JCI insight 0 41657312
2026 Exploring SIK2-CXCL5 interactions in neutrophils: A novel mechanism for modulating IL-23 and psoriasis progression. Immunology and cell biology 0 41867147
2026 A Review of SIK2 in Ovarian Cancer: Function and Emerging Targeted Therapies. OncoTargets and therapy 0 41908096
2026 The orally available SIK2/SIK3 inhibitor SK-124 increases bone mass in hypogonadal male mice. JBMR plus 0 41908158
2025 RETRACTION: SIK2-Positive Tumor Epithelial Cells in Breast Cancer Maybe Potential Anti-Cancer Messengers: A Systematic Analysis from a Single-Cell Perspective. Environmental toxicology 0 40059847
2025 SIK2 activates the autophagy‒apoptosis pathway through SP1 regulation to inhibit the progression of hepatocellular carcinoma. Frontiers in pharmacology 0 41111507
2025 Synergistic interplay and dual-target therapeutics: unraveling the coordinated network of SIK2 and PARP-1 in cancer development. Bioorganic chemistry 0 41265209
2024 SIK2: A Novel Negative Feedback Regulator of FGF2 Signaling. Advanced biology 0 39267218
2023 SIK2-positive tumor epithelial cells in breast cancer maybe potential anti-cancer messengers: A systematic analysis from a single-cell perspective. Environmental toxicology 0 37772720